KR20140145666A - Composition comprising natural complex of fucoxanthin, salix babylonica and low molecular weight alginate for preventing or treating of obesity - Google Patents

Abstract

The present invention relates to a composition containing a natural composite of fucoxanthin, Cortex ulmi pumilae, and low-molecular weight alginate, as an active ingredient, for preventing or treating obesity. The natural composite of fucoxanthin, Cortex ulmi pumilae, and low-molecular weight alginate according to the present invention has excellent obesity treatment effects, such as reduction of body weight and fat weight, lowering dietary efficiency, and improving blood lipid metabolism without hepatotoxicity, and thus can be useful to prevent or treat obesity.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention or treatment of obesity comprising a natural compound of alginic acid,

The present invention relates to a composition for preventing or treating obesity, which comprises a natural compound of gargoyle, currants and low molecular alginic acid as an active ingredient.

Obesity is a metabolic disorder caused by an imbalance between the consumption of food and the consumption of energy, which is an excess accumulation of fat in the body. Obesity is a phenomenon in which fat components consumed as food are decomposed and absorbed by lipase to accumulate in the cells or the accumulated fat induces the differentiation of lipid precursor cells into adipocytes, It occurs a lot when the number increases.

Obesity has been categorized as a disease requiring treatment by the World Health Organization (WHO) in 1996 and is responsible for various adult and chronic diseases such as diabetes, hypertension, hyperlipidemia, heart disease, arthritis, respiratory disease, sexual dysfunction and cancer . According to the results of the study, the obesity population was estimated at 400 million in 2005, and the world obesity population is estimated to increase to 700 million by 2015.

Treatment of obesity is known to be drug administration, surgery, diet and exercise therapy, among which the drug administration has the best effect. However, administration of such a drug, particularly a drug for the treatment of anti-obesity, has side effects such as headache or vomiting, so that it is difficult to use for a long period of time and the degree of side effects varies depending on the constitution.

In order to solve the above-mentioned side effects, researches on anti-obesity materials based on natural materials or foods having stability have been actively conducted.

On the other hand, yugunpi (CUP, Cortex ulmi pumilae ) belongs to Ulmaceae and refers to the bark or flesh of the cork layer of elm ( Ulmus davidiana var. Japonica Nakai). It has been widely used as analgesic or antiinflammatory agent because of its excellent anticancer and antioxidant effect.

Fucoxanthin, found in brown algae, is known to exhibit potent antineoplastic activity by inhibiting proliferation of neuroblastoma cells or by slowing the rate of proliferation.

Alginate is a substance extracted from seaweed, and various useful effects such as anti-inflammation, anti-cancer, and anti-edema have been reported, but there is a problem that the absorption rate in the body is remarkably low due to a large molecular weight. In order to solve this problem, various techniques for producing low molecular weight alginic acid by treating an enzyme with alginic acid have been studied. These low-molecular alginic acids have a lower viscosity and higher solubility than conventional alginic acid, and thus can be used in a variety of fields than conventional alginic acid.

Accordingly, the inventors of the present invention have been studying a natural material having no side effects and excellent anti-obesity effect, and found that a natural compound of garlic, yugaemyeo and low molecular alginic acid suppresses appetite and reduces body weight, inhibits adipocyte differentiation, And thus the present invention has been completed.

It is an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of obesity, which comprises a natural compound of garlic, lupus and low molecular alginic acid as an active ingredient.

Another object of the present invention is to provide a food composition for preventing or ameliorating obesity, which comprises a natural compound of a vegetable oil, a carnauba, and a low molecular weight alginic acid as an active ingredient.

In order to solve the above-mentioned problems, the present invention provides a pharmaceutical composition for preventing or treating obesity, which comprises a natural compound of garlic, lupus and low molecular alginic acid as an active ingredient.

The present invention also provides a food composition for preventing or ameliorating obesity, which comprises a natural compound of garlic, lupine and low molecular alginic acid as an active ingredient.

The natural complex of the kerosene, lupus and low molecular alginate according to the present invention has excellent obesity treatment effect, such as reducing weight and fat weight in an obesity animal model, reducing dietary efficiency, improving blood lipid metabolism without hepatotoxicity, And can be usefully used for preventing or treating obesity.

Brief Description of the Drawings Fig. 1 is a diagram showing the ability of the present invention to inhibit the adipocyte differentiation of a natural complex of a vegetable oil, a lycopene, and a low molecular weight alginate through oil red O staining.
FIG. 2 is a graph showing the effect of the natural complex of the present invention of the present invention on the pancreatic lipase activity (the ratio of weight ratio of calf: calyx: low molecular weight alginic acid = 1: 1: 1).
Fig. 3 is a graph showing the effect of the natural complex of the present invention of the present invention on the pancreatic lipase activity (the ratio of weight ratio of calf: calf: low molecular weight alginic acid = 2: 1: 1) of pancreatic lipase.
FIG. 4 is a graph showing the effect of the natural complex of the present invention of the present invention on the pancreatic lipase activity (the ratio of the weight ratio of the calf: calyx: low molecular weight alginic acid = 1: 2: 1).
FIG. 5 is a graph showing the effect of the natural complex of the present invention of the present invention on the pancreatic lipase activity (the ratio of the weight ratio of the calf: calf: low molecular weight alginic acid = 1: 1: 2).
FIG. 6 is a graph showing the effect of the natural complex of the present invention of the present invention on the pancreatic lipase activity (weight ratio of calf: calyx: low molecular weight alginic acid = 2.4: 5.7: 2).
FIG. 7 is a graph showing the effect of the natural compound of the present invention on the weight change during the experimental period.
FIG. 8 is a graph showing the effect of the natural compound of the present invention on the weight gain during the experimental period.
FIG. 9 is a graph showing the effect of the natural compound of the present invention of the present invention on the diet efficiency.
10 and 11 are graphs showing the effect of the natural compound of the present invention of the present invention on the abdominal fat weight change.
FIG. 12 is a graph showing the effect of the natural complex of the present invention of the present invention on the blood AST concentration.
FIG. 13 is a graph showing the effect of the natural complex of the present invention on the blood ALT concentration.
FIG. 14 is a graph showing the effect of the natural complex of the present invention on the blood triglyceride concentration.
FIG. 15 is a graph showing the effect of the natural complex of the present invention of the present invention on the total cholesterol concentration in blood.
FIG. 16 is a graph showing the effect of the natural complex of the present invention on the blood HDL-cholesterol concentration.
FIG. 17 is a graph showing the effect of the natural complex of the present invention on the blood LDL-cholesterol concentration.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for preventing or treating obesity comprising a natural complex of a vegetable oil, a carnauba, and a low molecular weight alginic acid as an active ingredient.

The composition comprises a pharmaceutical composition or a food composition.

Natural complexes of the present invention of the present invention can be obtained as follows.

The kelp can be separated from brown algae or used commercially without limitation. For example, the crude oil can be obtained from the powder of the noble starch by the following procedure. 60 to 80% (v / v) ethanol is added to the pulverized finely ground powder and the mixture is extracted at 75 to 95 ° C for 1 to 5 hours. The extracted concentrate is filtered using a filter, concentrated under reduced pressure, and the concentrated concentrate is dried using a drier to obtain a crude oil.

After removing the ghastmatrix, the remaining residue is added to the dried residue of the non-tragacanth powder with 1% Na ₂ CO ₃ and stirred at 100 rpm and 60 ° C for 4 hours. After 4 hours, distilled water at 60 ° C is added, centrifuged and the supernatant is recovered. The alginate solution is adjusted to pH 7 with acetic acid, and then an equal amount of ethanol is slowly added to the neutralized alginate solution along the wall surface. The solution is allowed to stand at room temperature for about 2 hours, and the suspended elution alginate suspended in the upper layer is recovered. After dissolving the obtained microorganism alginate in 0.2 M tris-HCl (pH 6.3, 3% alginate in 0.2 M tris-HCL), 3,000,000 units of alginate lyase (Sphingobacterium) were treated and stirred at 100 rpm and 37 ° C for 3 hours The reaction is terminated by treatment at 100 DEG C for 10 minutes to finally obtain low molecular weight alginic acid. The molecular weight of the low molecular weight alginic acid is preferably 100 to 2000, more preferably 180 to 1500.

Remove the foreign matter by washing with water, dry it in the shade and crush it. You can use it without restrictions such as cultivated or marketed. A suitable amount of solvent is added to the crushed rhubarb to be completely immersed. The extraction solvent is not limited thereto, but may be at least one solvent selected from water, alcohols having 1 to 4 carbon atoms, and a mixed solvent thereof, and is preferably a mixed solvent of water and alcohol. The solvent is added in an amount of about 2 to 20 times, preferably 3 to 10 times the weight of the crumbs of the crumbs and is heated at an extraction temperature of 50 to 100 DEG C, preferably 60 to 90 DEG C for about 1 to 8 hours, Is extracted for 2 to 6 hours. The process may be repeated two or more times for efficient extraction. Thereafter, the extract is filtered and concentrated under reduced pressure to obtain the final lupine extract.

The mixing ratio of the natural compound of the present invention is preferably in a weight ratio of 1: 3: 2 to 7: 1 to 3: 3, more preferably 2.3: 5.7: 2 to be.

The natural compound of the present invention according to the present invention inhibits differentiation of adipocytes, inhibits the activity of pancreatic lipase, reduces weight and fat weight in an animal model of obesity, decreases dietary efficiency, And has an excellent effect of treating obesity, such as improving blood lipid metabolism, and thus can be usefully used for preventing or treating obesity.

The composition of the present invention may contain at least one known active ingredient having a therapeutic effect of obesity together with a natural compound of garlic, lupus and low molecular alginic acid.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.

"Administration" in the present invention means providing the subject invention with a composition of the invention in any suitable manner.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the individual, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For a desired effect, the natural complex of the present invention can be administered in an amount of 10 mg / kg to 500 mg / kg per day. The composition may be administered once a day, or divided into several doses.

The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, muscular, subcutaneous injection.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention or treatment of obesity.

The composition of the present invention can be added to a health functional food for the purpose of preventing or improving obesity.

In the present invention, the term "health functional food" refers to a food having a biological control function such as prevention and improvement of disease, bio-defense, immunity, recovery after disease and aging inhibition.

When the natural compound of the present invention is used as a food additive, it is possible to add the natural compound of the above-mentioned petroleum jelly, lupsium and low molecular alginate as it is or in combination with other food or food ingredients, Lt; / RTI > The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, a natural compound of the present invention of the present invention is preferably added in an amount of 15% by weight or less, preferably 10% by weight or less based on the raw material. However, in the case of long-term intake for the purpose of health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred embodiments, experimental examples, and production examples are provided to facilitate understanding of the present invention. However, the following examples, experimental examples and preparation examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples, experimental examples and production examples.

Example 1: Preparation of natural complexes of carrageenan, curl and low molecular alginic acid

1-1. Manufacture of Calcined Powder

The kerosene was prepared from Bio Port Korea, Inc (Busan) and extracted from the southern hemisphere. More specifically, 70% ethanol was added to the crushed groundnut powder and extracted at 85 캜 for 3 hours. The extracted concentrate was filtered using a filter, followed by concentration under reduced pressure, and the concentrated concentrate was dried using a drier to finally obtain a vegetable oil.

1-2. Preparation of Root Extract

The yugaebok was washed with water to remove foreign matter, dried in the shade, and pulverized. 70% ethanol was added to crushed rhizome and extracted three times at 75 ℃ for 3 hours. The extract solution was filtered through Whatman No. 2 paper (Whatman international Ltd., England) to remove impurities, and the filtrate was concentrated under reduced pressure to finally obtain an extract of Rhodiola root.

1-3. Preparation of low molecular weight alginic acid powder

Low molecular weight alginate was prepared from Bio Port Korea, Inc (Busan). More specifically, 1 g Na ₂ CO ₃ was added to the dried residue of the ginger powder, and the mixture was stirred at 100 rpm and 60 ° C for 4 hours. After 4 hours, distilled water at 60 DEG C was added thereto, centrifuged, and the supernatant was recovered. The alginic acid solution was adjusted to pH 7 with acetic acid, and then an equal amount of ethanol was slowly added to the neutralized alginic acid solution along the wall surface. After standing at room temperature for about 2 hours, the suspended elution alginate suspended in the upper layer was recovered. The aliquots of alginate obtained were dissolved in 0.2 M tris-HCl (pH 6.3, 3% alginate in 0.2 M tris-HCL), treated with 3,000,000 units of alginate lyase (Sphingobacterium) and stirred at 100 rpm and 37 ° C for 3 hours Thereafter, the reaction was terminated by treatment at 100 DEG C for 10 minutes to finally obtain low molecular weight alginic acid.

1-4. Manufacture of natural complexes

The natural complexes were prepared by mixing the powders of the above-mentioned compositions (1-1 to 1-3), lupine extracts and low molecular weight alginic acid powders in the weight ratio shown in Table 1 below.

Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Low-molecular alginic acid 1: 1: 1 2: 1: 2 1: 2: 1 1: 1: 1 2.3: 5.7: 2

Example 2. Preparation of positive control group

The 'Fat down' product (hereinafter 'positive control') of CJ, which is a commercially available liquid diet supplement, was used as a positive control, which was concentrated under reduced pressure and dissolved in water.

Experimental Example 1. Inhibition of adipocyte differentiation

The oil red O staining was measured to confirm the ability of the natural composite of the kerosene, lupine and low molecular alginic acid prepared in Example 1-4 to inhibit adipocyte differentiation. More specifically, 3T3-L1 adipose precursor cells were cultured in a 35 mm culture dish in a 5% CO ₂ incubator at 37 ° C in a confluent state. Saturated clumped cells were treated with DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS and 0.1% streptomycin / penicillin and then further cultured for 2 days. The cells were then exchanged with differentiation medium (DMEM containing 10% FBS, 0.1% streptomycin / penicillin, 10 μg / mL insulin, 0.5 μM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine) , And Samples 1 to 5 prepared in Example 1 were treated respectively. After 2 days of incubation, the cells were exchanged with DMEM medium containing 10 / / ml insulin, treated with Samples 1 to 5 prepared in Example 1, respectively, and 3 to 5 Lt; / RTI > After confirming that the control group was completely differentiated into adipocytes, the medium was removed, and the cells were washed with phosphate buffered saline (PBS) and fixed with 10% formalin for 1 hour. After the formalin was completely removed, it was rinsed with 60% isopropanol, and oil red O working solution (SIGMA) was added thereto, followed by staining at room temperature for 10 minutes. At this time, the oil red O solution was prepared by dissolving 0.35 g of oil red O powder in 100 ml of isopropanol, diluting it in distilled water at a ratio of 6: 4, and then filtering. After dyeing, the oil red O solution was completely removed, washed with distilled water four times, and the dyeing state of the cells was confirmed by a microscope. The control group was treated with 0.5% DMSO. 　 The results are shown in Fig.

As shown in FIG. 1, it was confirmed that the group treated with the natural compound of the present invention of the present invention, the carrageenan and the low molecular weight alginic acid significantly inhibited differentiation into adipocytes as compared with the control group. Among them, And the ratio was 2.3: 5.7: 2.

Experimental Example 2. Measurement of pancreatic lipase inhibitory activity

The following experiments were conducted to confirm the pancreatic lipase inhibitory activity of the natural complexes of the carrageenan, lupine and low molecular alginate prepared in Example 1-4. As a reaction substrate, p-nitrophenyl dodecanoate (PNPD) was used and the degree of PNP color development was measured using a reaction in which PNPD was decomposed into PNP by lipase. More specifically, in a 1.5 ml tube, 10 μl of 0.25 M Tris-HCl (pH 7.7) buffer, 4 μl of 250 mM CaCl ₂ , 5 mM p-nitrophenyldodecanoate, lipase, Samples 1 to 5 were added and reacted. Then, sterilized distilled water (DW) was adjusted to a final volume of 200 μl of the reaction solution. The reaction was carried out in a heating block at 37 ° C for 0 min and 10 min, respectively, and the reaction was stopped by adding 3 μl of 20% SDS. It was centrifuged at 4 ° C and 15,000 rpm for 20 minutes. After centrifuging, 40 μl of DW was added to 160 μl of DW, diluted 5-fold, and then absorbance was measured at 412 nm using a UV spectrophotometer. Experiments were repeated three times for each natural compound. The values obtained after 10 minutes of reaction were subtracted from the values measured at 0 min and multiplied by 5-fold dilution values were used as data values. The control group was treated with 0.5% DMSO.

The pancreatic lipase inhibition rate was calculated according to the following equation. The results are shown in Figs. 2 to 6.

As shown in FIG. 2 to FIG. 6, it was confirmed that the pancreatic lipase inhibitory activity was increased according to the treatment concentration of the natural compound of the present invention of the present invention, root weevil and low molecular alginic acid.

Experimental Example 3 Obesity animal model design

3-1. Preparation of experimental animals

6-week-old C57BL / 6 male mice were purchased from Central Lab-Animal Inc., Seoul, Korea. C57Bl / 6J mice were housed in a constant environment at 24 ° C, 1 ° C, 50% humidity and 12h photoperiod. The mice were fed a normal diet for one week, and the experiment was started at 8 weeks of age.

3-2. Experimental design

The experiment was divided into 7 groups. Table 2 shows the composition of the normal and high fat diets, and Table 3 shows specific experimental groups. All of the normal diet, high fat diet, and water were fed autonomously, and positive control powder, root meal powder, kelp powder, low molecular weight alginate powder and natural complex were dissolved in water and orally administered at the same time every day. At this time, based on the results of Experimental Examples 1 and 2, the natural composite was prepared by mixing the components in a weight ratio of the following composition: a mixture of carrageenan: lupine: low molecular alginic acid = 2.3: 5.7: 2.

group Head Dosage Concentration (mg / kg BW) It's normal. 6 - It's a highland system. 6 - It's a highland system.
+ Positive control group 6
6
6 1000 mg / kg
2000 mg / kg
4000 mg / kg Polymer diet
+ Natural composite powder
(A weight ratio of a mixture of kelp: yuukee: low molecular alginic acid = 2.3: 5.7: 2) 6 250 mg / kg

Body weight was measured three times a week, and feed intake was measured twice a week. After the fasting state was maintained before the end of the experiment, plasma and tissue were separated.

Experimental Example 4. Weight gain analysis

In order to investigate the anti-obesity effect of the natural complex of the algae, lupine and low molecular alginic acid obtained in Example 1, the weight gain of the experimental animals of Experimental Example 3 was analyzed. The results are shown in Fig. 7 and Fig.

As shown in FIG. 7 and FIG. 8, there was no significant difference in weight between the groups at the initial stage of the experiment, but it was confirmed that a rapid increase in body weight was observed in the high-fat diet group compared to the high fat diet group The inventors of the present invention have found that the natural compound combination group of the present invention reduces the weight gain by about 17% as compared with the high fat diet group and the positive control group.

Experimental Example 5. Dietary efficiency analysis

In order to investigate the anti-obesity effect of the natural compound of the kelp, lupus and low molecular alginate obtained in Example 1, the dietary efficiency of the experimental animal of Experimental Example 3 was analyzed. The dietary efficiency was calculated by dividing the final weight gain by the total feed intake as shown in Equation 2 below. The results are shown in Fig.

As shown in FIG. 9, the dietary efficiency of the high-fat diet group was about 60% higher than that of the fat diet group. However, the dietary efficiency of the natural fat supplement group of the present invention was higher than that of the high fat diet group 22% lower than that of the control group. Therefore, it was confirmed that the natural compound administration group of the present invention of the present invention has a regulatory effect on obesity because the amount of increase in body weight is low when the feed intake amount is similar.

Experimental Example 6. Fat Weight Analysis

In order to investigate the anti-obesity effect of the natural complex of the carnosia, lupine and low molecular alginic acid obtained in Example 1, the abdominal fat of the experimental animal of Experimental Example 3 was extracted and weighed. A photograph of the abdominal fat obtained is shown in FIG. 10, and a measured value of abdominal fat weight is shown in FIG.

As shown in FIGS. 10 and 11, it was confirmed that the natural composite feed group of the present invention of the present invention had a remarkably reduced abdominal fat of about 20% or more as compared with that of the high fat diet group.

Experimental Example 7. Plasma Biochemical Analysis

In order to examine the effect of the natural complex of the carnosia, lupus and low molecular alginate obtained in Example 1 on the lipid metabolism in the blood, blood was collected from the abdominal vein of the experimental animal of Experimental Example 3 and subjected to plasma biochemical analysis . More specifically, the separated blood was left at room temperature for about 1 hour, and then the plasma was separated by centrifugation at 15,000 rpm for 5 minutes. It is known that AST (aminotransferase), alanine aminotransferase (ALT), triglyceride, total cholesterol, high density lipoprotein cholesterol (HDL-cholesterol) and low density lipoprotein cholesterol (LDL-cholesterol) ) Were measured with a blood biochemical analyzer.

7-1. Measure serum AST and ALT levels

Results of measurement of serum AST and ALT concentrations, which are blood liver toxicity index, are shown in FIGS. 12 and 13, respectively.

As shown in Figs. 12 and 13, it was confirmed that the natural composite feed group of the present invention of the present invention had lower AST and ALT levels than those of the high fat diet group. Therefore, it was confirmed that the natural complex of the present invention of the present invention is a safe substance free from hepatotoxicity.

7-2. Measure serum triglyceride, total cholesterol, HDL and LDL concentration

The results of measurement of serum triglyceride, total cholesterol, HDL and LDL concentration, which are indicators related to lipid metabolism, are shown in Figs. 14 to 17, respectively.

As shown in FIG. 14 and FIG. 15, it was confirmed that the neutral compositional group of the present invention of the present invention reduced the triglyceride and total cholesterol concentrations in the blood compared to the high fat diet group.

In addition, as shown in Figs. 16 and 17, it was confirmed that the serum concentration of HDL in the natural compound supplement group of the present invention was lower than that in the high fat diet group, but the serum LDL concentration was decreased . Therefore, it has been confirmed that the natural compound of the present invention of the present invention has the effect of improving the blood obesity index related to blood lipid metabolism.

Hereinafter, the pharmaceutical composition of the present invention and the preparation example of the food composition will be described, but the present invention is not intended to be limited but is specifically described.

Formulation Example 1. Preparation of pharmaceutical preparations

1-1. Manufacture of Powder

Natural complex of gargoyle, rhizome and low molecular alginate 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

Natural complex of gargoyle, rhizome and low molecular alginate 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Preparation of capsules

Natural complex of gargoyle, rhizome and low molecular alginate 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

1-4. Injection preparation

Natural complex of gargoyle, rhizome and low molecular alginate 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ 2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

1-5. Manufacture of liquid agent

Natural complex of gargoyle, rhizome and low molecular alginate 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation Example 2. Preparation of Food Composition

2-1. Manufacture of health food

Natural compound of kerosene, rhizome and low molecular alginic acid 100 mg

Vitamin mixture quantity

Vitamin A Acetate 70 g

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 g of vitamin B12

Vitamin C 10 mg

Biotin 10 g

Nicotinic acid amide 1.7 mg

Folate 50 g

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2-2. Manufacture of health drinks

Natural compound of kerosene, rhizome and low molecular alginic acid 100 mg

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3 g

Water quantification

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (5)

A pharmaceutical composition for the prevention or treatment of obesity comprising a natural compound of a carbohydrate, a carnauba and a low molecular weight alginic acid as an active ingredient. The pharmaceutical composition for preventing or treating obesity according to claim 1, wherein the natural complex is mixed at a weight ratio of 1: 3: 2 to 7: 1 to 3: 1: 3. The pharmaceutical composition for preventing or treating obesity according to claim 1, wherein the low molecular weight alginic acid has a molecular weight of 180 to 1500. A food composition for preventing or ameliorating obesity, which comprises a natural compound of a carbohydrate, a geranium and a low molecular weight alginic acid as an active ingredient. 5. The food composition for preventing or improving obesity according to claim 4, wherein the natural complex is mixed at a weight ratio of 1: 3: 2 to 7: 1 to 3: 1.

Images